PYXS
Pyxis Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.89
+9.12%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.7x
Market Cap
$324.46M
MomentumView details →
1D Return
+9.12%
YTD Return
+241.60%
RSI (14)
64.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.7x
Market Cap
$324.46M
RSI (14)
64.7
MomentumView details →
1D Return
+9.12%
YTD Return
+241.60%
SummaryUpdated Jun 1, 2026
Pyxis Oncology, Inc. (NASDAQ:PYXS) is a preclinical-stage biopharmaceutical company founded in 2018 and headquartered in Cambridge, Massachusetts. The company went public in October 2021 and focuses on developing innovative cancer therapies through two primary technological approaches: immune-oncology treatments and antibody drug conjugates. As a preclinical company, Pyxis is in the early stages of drug development, with its product candidates still undergoing laboratory and early clinical testing before potentially advancing to human trials and eventual commercialization.
Similar companies
Latest newsMore news →
Pyxis Oncology reported financial results for the quarter ended June 30, 2026.22d agoPyxis Oncology completed a private placement financing for up to $114 million, raising approximately $50 million in upfront gross proceeds to support patient follow-up and extend its cash runway into the second quarter of 2027.22d agoPyxis Oncology entered into a securities purchase agreement for a private placement of 19,600,153 common shares at $2.551 per share and warrants, expecting $50 million in gross upfront proceeds.65d ago